

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 881 289 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
02.12.1998 Bulletin 1998/49

(51) Int. Cl.⁶: **C12N 15/12**, C07K 14/705,
C07K 16/28, A61K 38/17,
C12Q 1/68, G01N 33/68

(21) Application number: **97309254.7**

(22) Date of filing: **18.11.1997**

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(30) Priority: **30.05.1997 US 866757**

(71) Applicant:
**SMITHKLINE BEECHAM CORPORATION
Philadelphia Pennsylvania 19103 (US)**

(72) Inventors:
• **Elshourbagy, Nabil A.
King of Prussia, Pennsylvania 19406 (US)**

• **Li, Xiaotong
King of Prussia, Pennsylvania 19406 (US)**
• **Bergsma, Derk, J.
King of Prussia, Pennsylvania 19406 (US)**

(74) Representative:
**Crump, Julian Richard John et al
FJ Cleveland,
40-43 Chancery Lane
London WC2A 1JQ (GB)**

(54) **Novel 7TM receptor (H2CAA71)**

(57) Novel 7TM receptor (H2CAA71) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Novel 7TM receptor (H2CAA71) polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, among others and diagnostic assays for such conditions.

EP 0 881 289 A2

Description

FIELD OF INVENTION

This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to G-protein coupled receptor family, hereinafter referred to as Novel 7TM receptor (H2CAA71). The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides.

BACKGROUND OF THE INVENTION

It is well established that many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers, e.g., cAMP (Lefkowitz, Nature, 1991, 351:353-354). Herein these proteins are referred to as proteins participating in pathways with G-proteins or PPG proteins. Some examples of these proteins include the GPC receptors, such as those for adrenergic agents and dopamine (Kobilka, B.K., et al., Proc. Natl Acad. Sci., USA, 1987, 84:46-50; Kobilka, B.K., et al., Science, 1987, 238:650-656; Bunzow, J.R., et al., Nature, 1988, 336:783-787), G-proteins themselves, effector proteins, e.g., phospholipase C, adenylyl cyclase, and phosphodiesterase, and actuator proteins, e.g., protein kinase A and protein kinase C (Simon, M.I., et al., Science, 1991, 252:802-8).

For example, in one form of signal transduction, the effect of hormone binding is activation of the enzyme, adenylyl cyclase, inside the cell. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP. GTP also influences hormone binding. A G-protein connects the hormone receptor to adenylyl cyclase. G-protein was shown to exchange GTP for bound GDP when activated by a hormone receptor. The GTP-carrying form then binds to activated adenylyl cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself, returns the G-protein to its basal, inactive form. Thus, the G-protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a clock that controls the duration of the signal.

The membrane protein gene superfamily of G-protein coupled receptors has been characterized as having seven putative transmembrane domains. The domains are believed to represent transmembrane α -helices connected by extracellular or cytoplasmic loops. G-protein coupled receptors include a wide range of biologically active receptors, such as hormone, viral, growth factor and neuroreceptors.

G-protein coupled receptors (otherwise known as 7TM receptors) have been characterized as including these seven conserved hydrophobic stretches of about 20 to 30 amino acids, connecting at least eight divergent hydrophilic loops. The G-protein family of coupled receptors includes dopamine receptors which bind to neuroleptic drugs used for treating psychotic and neurological disorders. Other examples of members of this family include, but are not limited to, calcitonin, adrenergic, endothelin, cAMP, adenosine, muscarinic, acetylcholine, serotonin, histamine, thrombin, kinin, follicle stimulating hormone, opsins, endothelial differentiation gene-1, rhodopsins, odorant, and cytomegalovirus receptors.

Most G-protein coupled receptors have single conserved cysteine residues in each of the first two extracellular loops which form disulfide bonds that are believed to stabilize functional protein structure. The 7 transmembrane regions are designated as TM1, TM2, TM3, TM4, TM5, TM6, and TM7. TM3 has been implicated in signal transduction.

Phosphorylation and lipidation (palmitoylation or farnesylation) of cysteine residues can influence signal transduction of some G-protein coupled receptors. Most G-protein coupled receptors contain potential phosphorylation sites within the third cytoplasmic loop and/or the carboxy terminus. For several G-protein coupled receptors, such as the β -adrenoreceptor, phosphorylation by protein kinase A and/or specific receptor kinases mediates receptor desensitization.

For some receptors, the ligand binding sites of G-protein coupled receptors are believed to comprise hydrophilic sockets formed by several G-protein coupled receptor transmembrane domains, said socket being surrounded by hydrophobic residues of the G-protein coupled receptors. The hydrophilic side of each G-protein coupled receptor transmembrane helix is postulated to face inward and form a polar ligand binding site. TM3 has been implicated in several G-protein coupled receptors as having a ligand binding site, such as the TM3 aspartate residue. TM5 serines, a TM6 asparagine and TM6 or TM7 phenylalanines or tyrosines are also implicated in ligand binding.

G-protein coupled receptors can be intracellularly coupled by heterotrimeric G-proteins to various intracellular enzymes, ion channels and transporters (see, Johnson et al., Endoc. Rev., 1989, 10:317-331). Different G-protein α -subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of G-protein coupled receptors have been identified as an important mechanism for the regulation of G-protein coupling of some G-protein coupled receptors. G-protein coupled receptors are found in numerous sites within a mammalian host.

Over the past 15 years, nearly 350 therapeutic agents targeting 7 transmembrane (7TM) receptors have been suc-

cessfully introduced onto the market.

This indicates that these receptors have an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further receptors which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome.

SUMMARY OF THE INVENTION

In one aspect, the invention relates to Novel 7TM receptor (H2CAA71) polypeptides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such Novel 7TM receptor (H2CAA71) polypeptides and polynucleotides. Such uses include the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, among others. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with Novel 7TM receptor (H2CAA71) imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate Novel 7TM receptor (H2CAA71) activity or levels.

DESCRIPTION OF THE INVENTION

Definitions

The following definitions are provided to facilitate understanding of certain terms used frequently herein.

"Novel 7TM receptor (H2CAA71)" refers, among others, to a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, or an allelic variant thereof.

"Receptor Activity" or "Biological Activity of the Receptor" refers to the metabolic or physiologic function of said Novel 7TM receptor (H2CAA71) including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said Novel 7TM receptor (H2CAA71).

"Novel 7TM receptor (H2CAA71) gene" refers to a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:1 or allelic variants thereof and/or their complements.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred

to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslational natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, *PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., *Posttranslational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Posttranslational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62.

"Variant" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. See, e.g.: (*COMPUTATIONAL MOLECULAR BIOLOGY*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS*, Smith, D.W., ed., Academic Press, New York, 1993; *COMPUTER ANALYSIS OF SEQUENCE DATA, PART I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY*, von Heinje, G., Academic Press, 1987; and *SEQUENCE ANALYSIS PRIMER*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in *Guide to Huge Computers*, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCS program package (Devereux, J., *et al.*, *Nucleic Acids Research* (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. *et al.*, *J Molec Biol* (1990) 215:403).

As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere

between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

Similarly, by a polypeptide having an amino acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

Polypeptides of the Invention

In one aspect, the present invention relates to Novel 7TM receptor (H2CAA71) polypeptides. The Novel 7TM receptor (H2CAA71) polypeptides include the polypeptide of SEQ ID NO:2; as well as polypeptides comprising the amino acid sequence of SEQ ID NO:2; and polypeptides comprising the amino acid sequence which have at least 80% identity to that of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95% identity to SEQ ID NO: 2. Furthermore, those with at least 97-99% are highly preferred. Also included within Novel 7TM receptor (H2CAA71) polypeptides are polypeptides having the amino acid sequence which have at least 80% identity to the polypeptide having the amino acid sequence of SEQ ID NO: 2 over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95% identity to SEQ ID NO: 2. Furthermore, those with at least 97-99% are highly preferred. Preferably Novel 7TM receptor (H2CAA71) polypeptides exhibit at least one biological activity of the receptor.

The Novel 7TM receptor (H2CAA71) polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, prosequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

Fragments of the Novel 7TM receptor (H2CAA71) polypeptides are also included in the invention. A fragment is a polypeptide having an amino acid sequence that entirely is the same as part, but not all, of the amino acid sequence of the aforementioned Novel 7TM receptor (H2CAA71) polypeptides. As with Novel 7TM receptor (H2CAA71) polypeptides, fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, and 101 to the end of Novel 7TM receptor (H2CAA71) polypeptide. In this context "about" includes the particularly recited ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at both extremes.

Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of Novel 7TM receptor (H2CAA71) polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus. Also preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Other preferred fragments are biologically active fragments. Biologically active fragments are those that mediate receptor activity, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those that are antigenic or immunogenic in an animal, especially in a human.

Preferably, all of these polypeptide fragments retain the biological activity of the receptor, including antigenic activity. Variants of the defined sequence and fragments also form part of the present invention. Preferred variants are those that vary from the referents by conservative amino acid substitutions -- i.e., those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.

The Novel 7TM receptor (H2CAA71) polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypep-

tides are well understood in the art.

Polynucleotides of the Invention

Another aspect of the invention relates to Novel 7TM receptor (H2CAA71) polynucleotides. Novel 7TM receptor (H2CAA71) polynucleotides include isolated polynucleotides which encode the Novel 7TM receptor (H2CAA71) polypeptides and fragments, and polynucleotides closely related thereto. More specifically, Novel 7TM receptor (H2CAA71) polynucleotide of the invention include a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:1 encoding a Novel 7TM receptor (H2CAA71) polypeptide of SEQ ID NO: 2, and polynucleotide having the particular sequence of SEQ ID NO:1. Novel 7TM receptor (H2CAA71) polynucleotides further include a polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the Novel 7TM receptor (H2CAA71) polypeptide of SEQ ID NO:2 over its entire length, and a polynucleotide that is at least 80% identical to that having SEQ ID NO:1 over its entire length. In this regard, polynucleotides at least 90% identical are particularly preferred, and those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred. Also included under Novel 7TM receptor (H2CAA71) polynucleotides are a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO:1 to hybridize under conditions useable for amplification or for use as a probe or marker. The invention also provides polynucleotides which are complementary to such Novel 7TM receptor (H2CAA71) polynucleotides.

Novel 7TM receptor (H2CAA71) of the invention is structurally related to other proteins of the G-protein coupled receptor family, as shown by the results of sequencing the cDNA of Table 1 (SEQ ID NO:1) encoding human Novel 7TM receptor (H2CAA71). The cDNA sequence of SEQ ID NO:1 contains an open reading frame (nucleotide numbers 483 to 2415) encoding a polypeptide of 644 amino acids (SEQ ID NO:2). The amino acid sequence of Table 2 (SEQ ID NO:2) has about 27% identity (using FASTA) in 571 amino acid residues with Bovine follicle stimulating hormone receptor. Houde A 1994 Mol. Reprod. Dev.,39, 127-135. The nucleotide sequence of Table 1 (SEQ ID NO:1) has about 60% identity (using FASTA) in 80 nucleotide residues with Bovine follicle stimulating hormone receptor. Houde A 1994 Mol. Reprod. Dev.,39, 127-135.

Table 1^a

5
1 GCTTCCATCC TAATACAACT CACTATAGGG CTCGAGCGGC CGCCCGGGCA
51 GGTGCTTGAC GGAGGTGCCT GTGCACCCCC TCAGCAATCT GCCCACCCTA
10
101 CAGGCGCTGA CCCTGGCTCT CAACAAGATC TCAAGCATCC CTgACTTTGC
151 ATTTACCAAC CTTTCAAGCC TGGTAgtTCT GCATCTTCAT AACAAATAAA
15
201 TTAgtAAGCCT GAGTCAACAC TGTTTTGATG GACTAgATaA CCTGGAGACC
251 TTAgtACTTGA ATTATAATAA CTGGGGGAA TTTCTTCAGG CTATTAAAGC
20
301 CCTTCCTAGC CTTAAAgAGC TAGGATTTCA TAGTAATTCT ATTTCTGTTA
351 TCCCTATGGA GCATTTGATG GTAATCCACT CTTAAgAACT ATACATTTGT
25
401 ATGATAATCC TCTGTCTTTT GTGGGGAACT CAGCATTTCA CAAttTATCT
451 GATCTTCATT CCCTAGTCAT TcGTGGTGCA AGCATGGTGC AGCAGTTCCC
30
501 CAATCTTACA GGAAGTGTCC ACCTGGAAAG TCTGACTTTG ACAGGTACAA
551 AGATAAGCAG CATACCTAAT AATTTGTGT C AAGAACAAAA GATGCTTAGG
35

40

45

50

55

5

10

15

20

25

30

35

40

45

50

55

601 ACTTTGGACT TGTCTTACAA TAATATAAGA GACCTTCCAA GTTTTAATGG
 651 TTGCCATGCT CTGGAAGAAA TTTCTTTACA GCGTAATCAA ATCTACCAAA
 701 TAAAGGAAGG CACCTTTCAA GGCTGATAT CTCTAAGGAT TCTAGATCTG
 751 AGTAGAAACC TGATACATGA AATTACAGT AGAGCTTTTG CCACACTTGG
 801 GCCAATAA_{ct} AAC_cTAGAT_g TAAGTTTCAA tGAATTAACT TC_cTTTC_{ct}A
 851 CGGAAGGC_{ct} GAATGGG_cTA AATCAACTGA AACTGGTGGG CAACTTCAAG
 901 cTGAAAGAAG CCTTAGCAGC AAAAGACTT_t GTTAACCTCa GGTCTTTATC
 951 AGTACCATAT GCTTATCAGT GCTGTGCATT TtGGGGTtGT GA_cTCTTATG
 1001 CAAATTTAAA CACAGAAGAT AACAGCCTCC AGGACCACAG TGTGGCACAG
 1051 GAGAAAGGTA CTGCTGATGC AGCAAATGTC ACAAGCACTC TTGAAAATGA
 1101 AGAACATAGT CAAATAATTA TCCATTGTAC ACCTTCAACA GGTGCTTTTA
 1151 AGCCCTGTGA ATATTTACTG GGAAGCTGGA TGATTCGTCT TACTGTGTGG
 1201 TTCATTTTCT TGCTTGCAAT ATTTTCAAC CTGCTTGTTA TTTTAACAAC
 1251 ATTTGCATCT TGTACATCAC TGCCTTCGTC CAAATTGTTT ATAGGCTTGA
 1301 TTTCTGTGTC TAACTTATTC ATGGGAATCT ATACTGGCAT CCTAACTTTT
 1351 CTTGATGCTG TGTCTGGGG CAGATTCGCT GAATTTGGCA TTTGGTGGGA
 1401 AACTGGCAGT GGCTGCAAAG TAACTGGGTT TCTTGCA_gTT TTCTCCTCAG
 1451 AAAGTGCCAT ATTTTATTA ATGCTA_gCAA CTGTGAAAG AA_gCTTATCT
 1501 GCAAAGATA TAATGAAAAA TGGAAGAGC AATCATCTCA AACAGTTCCG
 1551 GGTTGCTGCC CTTTGGCTT TCCTAGGTGC TACAGTAACA GGCTGTTTTC
 1601 CCCTTTTCCA TAGAGGGGAA TATTCTGCAT CACCCCTTTG TTTGCCATTT

5

1651 CCTACAGGTG AAACGCCAT C ATTAGGATT C ACTGTAACT TAGTGCTATT

1701 AAAC TACTA GCATTTTTAT TAATGGCOGT TATCTACACT AAGCTATACT

10

1751 GCAACTTGGA AAAAGAGGAC CTCTCAGAAA ACTCACAAT C TAGCATGATT

1801 AAGCATGT CG CTGGCTAAT CTTACCAAT TGCATCTTTT TCTGCCCTGT

15

1851 GGCGTTTTTT TCAATTGCAC CATTGATCAC TGCAATCTCT ATCAGCCCCG

1901 AAATAATGAA GTCTGTTACT CTGATATTTT TTCCATTGCC TGCTTGCCCTG

20

1951 AATCCAGTCC TGTATGTTTT CTTCAACCCA AAGTTTAAAG AAGACTGGAA

2001 GTTACTGAAG CGACGTGTTA CCAAGAAAAG TGGATCAGTT TCAGTTTCCA

25

2051 TCAGTAGCCA AGGTGGTTGT CTGGAACAGG ATTTCTACTA CGACTGTGGC

2101 ATGTACTCAC ATTTGCAGGG CAACCTGACT GTTGCGACT GCTGCGAATC

30

2151 GTTTCTTTTA ACAAAGCCAG TATCATGCAA ACACTTGATA AAATCACACA

2201 GCTGTCCTGC ATTGGCAGTG GCTTCTTGCC AAAGACCTGA GGGCTACTGG

35

2251 TCGACTGTG GCACACAGT C GGCCCACTCT GATTATGCAG ATGAAGAAGA

2301 TTCCTTTGTC TCAGACAGTT CTGACCAGGT GCAGGCCTGT GGACGAGCCT

40

2351 GCTTCTACCA GAGTAGAGGA TTCCCTTTGG TCGCTATGC TTACAATCTA

2401 CCAAGAGTTA AAGACTGAAC TACTGTGTGT GTAACCGTTT CCCCCGTCAA

45

2451 CCAAATCAG TGTTTATAGA GTGAACCCTA TTCTCATCTT TCATCTGGGA

2501 AGCACTTCTG TAATCACTGC CTGGTGT CAC TTAGAAGAAG GAGAGGTGGC

50

2551 AGTTTATTT C TCAAACCAGT CATTTTCAA GAACAGGTGC CTAATTATA

2601 AATTGGTGAA AAATGCAATG TCCAAGCAAT GTATGATCTG TTTGAAACAA

55

5

2651 ATATATGACT TGAAAAGGAT CTTAGGTGTA GTAGAGCAAT ATAATGTTAG

2701 TTTTTTCTGA TCCATAAGAA GCAAATTTAT ACCTATTGT GTATTAAGCA

2751 CAAGATAAAG AACAGCTGTT AATATTTTTT AAAAATCTAT TTTAAAATGT

10

2801 GATTTTCTAT AACTGAAGAA AATATCTTGC TAATTTTACC TAATGTTTCA

2851 TCCTTAATCT CAGGACAACT TACTGCAGGG CCAAAAAAGG GACTGTCCCA

15

2901 GCTAGAACTG TGAGAGTATA CATAGGCATT ACTTTATTAT GTTTTCACTT

2951 GCCATCCTTG ACATAAGAGA ACTATAAATT TTGTTTAAGC AATTTATAAA

20

3001 TCTAAACCT GAAGATGTTT TTAAACAAT ATTAAACAGCT GTTAGGTTAA

3051 AAAAATAGCT GGACATTTGT TTTCACTCAT TATACATTGC TTTGGTCCAA

25

3101 TCAGTAATTT TTTCTTAAGT GTTTTGTGAT TACACTACTA GAAAAAAGT

3151 AAAAGGCTAA TTGCTGTGTG GGTTTAGTCG ATTTGGCTAA ACTACTAACT

30

3201 AATGTGGGGG TTTAATAGTA TCTGAGGGAT TTGGTGGCTT CATGTAATGT

3251 TCTCATTAAAT GAATACTTCC TAATATCGTT GGCTCTACTA ATATTTTCCA

35

3301 ATTTGCTGGG ATGTCACCTA GCAATAGCTT GGATTATATA GAAAGTAAAC

3351 TGTGGTCAAT ACTTGCATTT AATTAGACGA AACGGGGAGT AATTATGACA

40

3401 CGAAGTACTT ATGTTTATTT CTTAGTGAGC TGGATTATCT TGAACCTGTG

3451 CTATTAAATG GAAATTTCCA TACATCTTCC CCATACTATT TTTTATAAAA

45

3501 GAGCCTATTC AATAGCTCAG AGGTTGAACT CTGGTTAAAC AAGATAATAT

3551 GTTATTAATA AAAATAGAAG AAGAAAGAAT AAAGCTTAGT CCTGTGTCTT

50

3601 TAAAAATTAA AAATTTTACT TGATTCCCAT CTATGGGCTT TAGACCTATT

3651 ACTGGGTGGA GTCTTAAAGT TATAATTGTT CAATATGTTT TTTGAACAGT

55

3701 GTGCTAAATC AATAGCAAAC CCACTGCCAT ATTAGTTATT CTGAATATAC
3751 TAAAAAAATC CAGCTAGATT GCAGTTTAAAT AATTAAACTG TACATACTGT
3801 GCATATAATG AATTTTTATC TTATGTAAAT TATTTTTAGA ACACAAGTTG
3851 GGAAATGTGG CTTCTGTTCA TTTGTTTAA TTAAAGCTAC CTCCTAAACT
3901 ATAGTGGCTG CCAGTAGCAG ACTGTTAAAT TGTGGTTTAT ATACTTTTGT
3951 CATTGTAAAT AGTCTTGTT GTACATTGTC AGTGTAAATA AACAGAATC
4001 TTTGTATATC AAAATCATGT AGTTTGTATA AAATGTGGGA AGGATTTATT
4051 TACAGTGTGT TGTAAATTTG TAAGGCCAAC TATTACAAG TTTTAAAAAT
4101 TGCTATCATG TATATTTACA CATCTGATAA ATATTAAATC ATAACTTGGT
4151 AAGAAACTCC TAATTAAAAG GTTTTTTCCA AAAAAAAAAA AAAAAAAAAA
4201 AAA

^a A nucleotide sequence of a human Novel 7TM receptor (H2CAA71) (SEQ ID NO: 1).

Table 2^b

1 MVQQFPNLG TVHLESLTLT GTKISSIPNN LCQEQKMLRT LDLSYNNIR
51 LP SFNGCHAL EEI SLQRNQI YQIKEGTFQG LISLRILDLS RNLIHEIHSR
101 AFATLGPITN LDVSFNELTS FPTEGLNGLN QKLVGNFKL KEALAAKDFV
151 NLRSLVPIYA YQCCAFWGD SYANLNTEDN SLQDHSVAQE KGTADAANVT
201 STLENEEH SQ IIIHCTPSTG AFKPC EYLLG SWMIRLTVWF IFLVALFFNL
251 LVILTTFASC TSLPSSKLF IGLISVSNLFM GIYTGILTFL DAVSWGRFAE

	301	FGIWWETGSG	CKVTGFLAVF	SSESAIFLLM	LATVERLSA	KDIMKNGKSN
5		351	HLKQFRVAAL	LAFLGATVTG	CFPLFHRGEY	SASPLCLPFP
					TGETPSLGFT	
		401	VTLLVLLNSLA	FLLMAVIYTK	LYCNLEKEDL	SENSQSSMIK
					HVAWLIFTNC	
10		451	IFFCPVAFFS	FAPLITAI SI	SPEIMKSVTL	IFFPLPACLN
					PVLYVFFNPK	
		501	FKEDWKLK R	RVTKKSGSVS	VSISSQGGCL	EQDFYYDCGM
					YSHLQGNLTV	
15		551	QDCCESFLLT	KPVSKHLLK	SHSCPALAVA	SCQRPEGYWS
					DCGTQSAHSD	
		601	YADEEDSFVS	DSSDQVQACG	RACFYQSRGF	PLVRYAYNLP
					RVKD	
20						

An amino acid sequence of a human Novel 7TM receptor (H2CAA71) (SEQ ID NO: 2).

One polynucleotide of the present invention encoding Novel 7TM receptor (H2CAA71) may be obtained using standard cloning and screening, from a cDNA library derived from mRNA in cells of Human placenta using the expressed sequence tag (EST) analysis (Adams, M.D., *et al. Science* (1991) 252:1651-1656; Adams, M.D. *et al. Nature*, (1992) 355:632-634; Adams, M.D., *et al. Nature* (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

The nucleotide sequence encoding Novel 7TM receptor (H2CAA71) polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in Table 1 (nucleotide number 483 to 2415 of SEQ ID NO:1), or it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2.

When the polynucleotides of the invention are used for the recombinant production of Novel 7TM receptor (H2CAA71) polypeptide, the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al., Proc Natl Acad Sci USA* (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Further preferred embodiments are polynucleotides encoding Novel 7TM receptor (H2CAA71) variants comprising the amino acid sequence of Novel 7TM receptor (H2CAA71) polypeptide of Table 2 (SEQ ID NO:2) in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination.

The present invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.

Polynucleotides of the invention, which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO:1 or a fragment thereof, may be used as hybridization probes for cDNA and genomic DNA, to isolate full-length cDNAs and genomic clones encoding Novel 7TM receptor (H2CAA71) and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the Novel 7TM receptor (H2CAA71) gene. Such hybridization techniques are known to those of skill in the art. Typically these nucleotide sequences are 80% identical, preferably 90% identical, more preferably 95% identical to that of the referent. The probes generally will comprise at least 15 nucleotides. Preferably, such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.

In one embodiment, to obtain a polynucleotide encoding Novel 7TM receptor (H2CAA71) polypeptide comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the SEQ ID NO: 1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Thus in another aspect, Novel 7TM receptor (H2CAA71) polynucleotides of the present invention further include a nucleotide sequence comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having SEQ ID NO: 1 or a fragment thereof. Also included with Novel 7TM receptor (H2CAA71) polypeptides are polypeptides comprising amino acid sequences encoded by a nucleotide sequence obtained by the above hybridization condition. Such hybridization techniques are well known to those of skill in the art. Stringent hybridization conditions are as defined above or alternatively conditions under overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

The polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to animal and human disease.

Vectors, Host Cells, Expression

The present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, and host cells which are genetically engineered with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., *BASIC METHODS IN MOLECULAR BIOLOGY* (1986) and Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used. Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL* (*supra*).

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If the Novel 7TM receptor (H2CAA71) polypeptide is to be expressed for use in screening assays, generally, it is preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If Novel 7TM receptor (H2CAA71) polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide; if produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Novel 7TM receptor (H2CAA71) polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

Diagnostic Assays

This invention also relates to the use of Novel 7TM receptor (H2CAA71) polynucleotides for use as diagnostic reagents. Detection of a mutated form of Novel 7TM receptor (H2CAA71) gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression of Novel 7TM receptor (H2CAA71). Individuals carrying mutations in the Novel 7TM receptor (H2CAA71) gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled Novel 7TM receptor (H2CAA71) nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers *et al.*, *Science* (1985) 230:1242. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method. See Cotton *et al.*, *Proc Natl Acad Sci USA* (1985) 85: 4397-4401. In another embodiment, an array of oligonucleotide probes comprising Novel 7TM receptor (H2CAA71) nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability. (See for example: M.Chee *et al.*, *Science*, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome through detection of mutation in the Novel 7TM receptor (H2CAA71) gene by the methods described.

In addition, infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of Novel 7TM receptor (H2CAA71) polypeptide or Novel 7TM receptor (H2CAA71) mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as an Novel 7TM receptor (H2CAA71), in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Chromosome Assays

The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, *Mendelian Inheritance in Man* (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

Antibodies

The polypeptides of the invention or their fragments or analogs thereof or cells expressing them can also be used as immunogens to produce antibodies immunospecific for the Novel 7TM receptor (H2CAA71) polypeptides. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against the Novel 7TM receptor (H2CAA71) polypeptides can be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

Antibodies against Novel 7TM receptor (H2CAA71) polypeptides may also be employed to treat infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, among others.

Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with Novel 7TM receptor (H2CAA71) polypeptide, or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, among others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering Novel 7TM receptor (H2CAA71) polypeptide via a vector directing expression of Novel 7TM receptor (H2CAA71) polynucleotide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases.

Further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a Novel 7TM receptor (H2CAA71) polypeptide wherein the composition comprises a Novel 7TM receptor (H2CAA71) polypeptide or Novel 7TM receptor (H2CAA71) gene. The vaccine formulation may further comprise a suitable carrier. Since Novel 7TM receptor (H2CAA71) polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Screening Assays

The Novel 7TM receptor (H2CAA71) polypeptide of the present invention may be employed in a screening process for compounds which bind the receptor and which activate (agonists) or inhibit activation of (antagonists) the receptor polypeptide of the present invention. Thus, polypeptides of the invention may also be used to assess the binding of

small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See Coligan *et al.*, *Current Protocols in Immunology* 1(2):Chapter 5 (1991).

Novel 7TM receptor (H2CAA71) polypeptides are responsible for many biological functions, including many pathologies. Accordingly, it is desirable to find compounds and drugs which stimulate Novel 7TM receptor (H2CAA71) on the one hand and which can inhibit the function of Novel 7TM receptor (H2CAA71) on the other hand. In general, agonists are employed for therapeutic and prophylactic purposes for such conditions as infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome. Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome.

In general, such screening procedures involve producing appropriate cells which express the receptor polypeptide of the present invention on the surface thereof. Such cells include cells from mammals, yeast, *Drosophila* or *E. coli*. Cells expressing the receptor (or cell membrane containing the expressed receptor) are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response.

One screening technique includes the use of cells which express receptor of this invention (for example, transfected CHO cells) in a system which measures extracellular pH or intracellular calcium changes caused by receptor activation. In this technique, compounds may be contacted with cells expressing the receptor polypeptide of the present invention. A second messenger response, e.g., signal transduction, pH changes, or changes in calcium level, is then measured to determine whether the potential compound activates or inhibits the receptor.

Another method involves screening for receptor inhibitors by determining inhibition or stimulation of receptor-mediated cAMP and/or adenylate cyclase accumulation. Such a method involves transfecting a eukaryotic cell with the receptor of this invention to express the receptor on the cell surface. The cell is then exposed to potential antagonists in the presence of the receptor of this invention. The amount of cAMP accumulation is then measured. If the potential antagonist binds the receptor, and thus inhibits receptor binding, the levels of receptor-mediated cAMP, or adenylate cyclase, activity will be reduced or increased.

Another method for detecting agonists or antagonists for the receptor of the present invention is the yeast based technology as described in U.S. Patent 5,482,835 which is incorporated herein by reference.

The assays may simply test binding of a candidate compound wherein adherence to the cells bearing the receptor is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the receptor, using detection systems appropriate to the cells bearing the receptor at their surfaces. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist in the presence of the candidate compound is observed.

The Novel 7TM receptor (H2CAA71) cDNA, protein and antibodies to the protein may also be used to configure assays for detecting the effect of added compounds on the production of Novel 7TM receptor (H2CAA71) mRNA and protein in cells. For example, an ELISA may be constructed for measuring secreted or cell associated levels of Novel 7TM receptor (H2CAA71) protein using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents which may inhibit or enhance the production of Novel 7TM receptor (H2CAA71) (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues. Standard methods for conducting screening assays are well understood in the art.

Examples of potential Novel 7TM receptor (H2CAA71) antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligand of the Novel 7TM receptor (H2CAA71), e.g., a fragment of the ligand, or small molecules which bind to the receptor but do not elicit a response, so that the activity of the receptor is prevented.

Prophylactic and Therapeutic Methods

This invention provides methods of treating abnormal conditions such as, infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris;

myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, related to both an excess of and insufficient amounts of Novel 7TM receptor (H2CAA71) activity.

If the activity of Novel 7TM receptor (H2CAA71) is in excess, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit activation by blocking binding of ligands to the Novel 7TM receptor (H2CAA71), or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of Novel 7TM receptor (H2CAA71) polypeptides still capable of binding the ligand in competition with endogenous Novel 7TM receptor (H2CAA71) may be administered. Typical embodiments of such competitors comprise fragments of the Novel 7TM receptor (H2CAA71) polypeptide.

In still another approach, expression of the gene encoding endogenous Novel 7TM receptor (H2CAA71) can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, *J Neurochem* (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Alternatively, oligonucleotides which form triple helices with the gene can be supplied. See, for example, Lee *et al.*, *Nucleic Acids Res* (1979) 6:3073; Cooney *et al.*, *Science* (1988) 241:456; Dervan *et al.*, *Science* (1991) 251:1360. These oligomers can be administered *per se* or the relevant oligomers can be expressed *in vivo*.

For treating abnormal conditions related to an under-expression of Novel 7TM receptor (H2CAA71) and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates Novel 7TM receptor (H2CAA71), i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of Novel 7TM receptor (H2CAA71) by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For overview of gene therapy, see Chapter 20, *Gene Therapy and other Molecular Genetic-based Therapeutic Approaches*, (and references cited therein) in *Human Molecular Genetics*, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of Novel 7TM receptor (H2CAA71) polypeptides in combination with a suitable pharmaceutical carrier.

Formulation and Administration

Peptides, such as the soluble form of Novel 7TM receptor (H2CAA71) polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier. Such formulations comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and is well within the skill of the art. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

Preferred forms of systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 μ g/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a

polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

Examples

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples illustrate, but do not limit the invention.

Example 1: Gene Cloning

The H2CAA71 EST (# 898510) was identified from the Human Genome Sciences (HGS) database as a potential 7TM receptor and has the following sequence:

```

1      GGCACGAGAA CGCCATCATT AGGATTCACT GTAACGTTAG TGCTATTAAA
51     CTCACTAGCA TTTTATTAA TGGCCGTTAT CTACACTAAG CTATACTGCA
101    ACTTGGA AAA AGAGGACCTC TCAGAAA ACT CACAATCTAG CATGATT AAG
151    CATGTGCTT GGCTAATCTT CACCAATTGC ATCTTTTCT GCCCTGTGGC
201    GTTTTTTCA TTTGCACCAT TGATCACTGC AATCTCTATC AGCCCCGAAA
251    TAATGAAGTC TGTTACTCTG ATATTTTTTC CATTGCCTGC TTGCCTGAAT
301    CCACTCCTGT ATGTTTTCTT CAACCCAAAG TTAAAGAGG ACTGGGAAGT
351    TACTGAGGCG ACGTGTTTAC CAGGAAAAGT GGGTCCAGTT TCAGTTNCCN
401    CATAGNCCAG GTGGTTTCTG GAACAGGGTT TATATAGGGT TTGGGATGTA
451    CTCACATTNG AAGGCAACCT GAC (SEQ ID NO: 3)

```

This clone was ordered and sequenced completely. Analysis of the sequence revealed that the clone is a truncated clone. Therefore, oligonucleotides (5') were designed at the 5' end of the clone. This oligo was: AGTTAGGATGCCAG-TATAGATTCCC (SEQ ID NO:4). This oligo was used to PCR a 1.3 kb 5' fragment using the Marathon technique (Clontech). The 5' PCR fragment was subcloned into pCR2.1 vector and were sequenced. This fragment was found to overlap with the original H2CAA71 truncated clone. The full length clone is of 4.2 kb in length and it encodes a protein of 644 amino acids.

Example 2: Mammalian Cell Expression

The receptors of the present invention are expressed in either human embryonic kidney 293 (HEK293) cells or adherent dhfr CHO cells. To maximize receptor expression, typically all 5' and 3' untranslated regions (UTRs) are removed from the receptor cDNA prior to insertion into a pCDN or pCDNA3 vector. The cells are transfected with individual receptor cDNAs by lipofectin and selected in the presence of 400 mg/ml G418. After 3 weeks of selection, individual clones are picked and expanded for further analysis. HEK293 or CHO cells transfected with the vector alone serve as negative controls. To isolate cell lines stably expressing the individual receptors, about 24 clones are typically selected and analyzed by Northern blot analysis. Receptor mRNAs are generally detectable in about 50% of the G418-resistant clones analyzed.

Example 3 Ligand bank for binding and functional assays.

A bank of over 200 putative receptor ligands has been assembled for screening. The bank comprises: transmitters, hormones and chemokines known to act via a human seven transmembrane (7TM) receptor; naturally occurring compounds which may be putative agonists for a human 7TM receptor, non-mammalian, biologically active peptides for which a mammalian counterpart has not yet been identified; and compounds not found in nature, but which activate 7TM receptors with unknown natural ligands. This bank is used to initially screen the receptor for known ligands, using both functional (i.e. calcium, cAMP, microphysiometer, oocyte electrophysiology, etc., see below) as well as binding assays.

Example 4: Ligand Binding Assays

Ligand binding assays provide a direct method for ascertaining receptor pharmacology and are adaptable to a high throughput format. The purified ligand for a receptor is radiolabeled to high specific activity (50-2000 Ci/mmol) for binding studies. A determination is then made that the process of radiolabeling does not diminish the activity of the ligand towards its receptor. Assay conditions for buffers, ions, pH and other modulators such as nucleotides are optimized to establish a workable signal to noise ratio for both membrane and whole cell receptor sources. For these assays, specific receptor binding is defined as total associated radioactivity minus the radioactivity measured in the presence of an excess of unlabeled competing ligand. Where possible more than one competing ligand is used to define residual non-specific binding.

Example 5: Functional Assay in *Xenopus* Oocytes

Capped RNA transcripts from linearized plasmid templates encoding the receptor cDNAs of the invention are synthesized in vitro with RNA polymerases in accordance with standard procedures. In vitro transcripts are suspended in water at a final concentration of 0.2 mg/ml. Ovarian lobes are removed from adult female toads, Stage V defolliculated oocytes are obtained, and RNA transcripts (10 ng/oocyte) are injected in a 50 nl bolus using a microinjection apparatus. Two electrode voltage clamps are used to measure the currents from individual *Xenopus* oocytes in response to agonist exposure. Recordings are made in Ca²⁺ free Barth's medium at room temperature. The *Xenopus* system can be used to screen known ligands and tissue/cell extracts for activating ligands.

Example 6: Microphysiometric Assays

Activation of a wide variety of secondary messenger systems results in extrusion of small amounts of acid from a cell. The acid formed is largely as a result of the increased metabolic activity required to fuel the intracellular signaling process. The pH changes in the media surrounding the cell are very small but are detectable by the CYTOSENSOR microphysiometer (Molecular Devices Ltd., Menlo Park, CA). The CYTOSENSOR is thus capable of detecting the activation of a receptor which is coupled to an energy utilizing intracellular signaling pathway such as the G-protein coupled receptor of the present invention.

Example 7: Extract/Cell Supernatant Screening

A large number of mammalian receptors exist for which there remains, as yet, no cognate activating ligand (agonist). Thus, active ligands for these receptors may not be included within the ligands banks as identified to date. Accordingly, the 7TM receptor of the invention is also functionally screened (using calcium, cAMP, microphysiometer, oocyte electrophysiology, etc., functional screens) against tissue extracts to identify natural ligands. Extracts that produce positive functional responses can be sequentially subfractionated until an activating ligand is isolated identified.

Example 8: Calcium and cAMP Functional Assays

7TM receptors which are expressed in HEK 293 cells have been shown to be coupled functionally to activation of PLC and calcium mobilization and/or cAMP stimulation or inhibition. Basal calcium levels in the HEK 293 cells in receptor-transfected or vector control cells were observed to be in the normal, 100 nM to 200 nM, range. HEK 293 cells expressing recombinant receptors are loaded with fura 2 and in a single day > 150 selected ligands or tissue/cell extracts are evaluated for agonist induced calcium mobilization. Similarly, HEK 293 cells expressing recombinant receptors are evaluated for the stimulation or inhibition of cAMP production using standard cAMP quantitation assays. Agonists presenting a calcium transient or cAMP fluctuation are tested in vector control cells to determine if the response is unique to the transfected cells expressing receptor.

SEQUENCE LISTING

5

(1) GENERAL INFORMATION

10

(i) APPLICANT: SmithKline Beecham Corporation

(ii) TITLE OF THE INVENTION: NOVEL 7TM RECEPTOR (H2CAA71)

15

(iii) NUMBER OF SEQUENCES: 4

(iv) CORRESPONDENCE ADDRESS:

20

(A) ADDRESSEE: F J Cleveland & Company

(B) STREET: 40/43 Chancery Lane

(C) CITY: London

(D) STATE: -

25

(E) COUNTRY: United Kingdom

(F) POST CODE: WC2A 1JQ

(v) COMPUTER READABLE FORM:

30

(A) MEDIUM TYPE: Diskette

(B) COMPUTER: IBM Compatible

(C) OPERATING SYSTEM: DOS

(D) SOFTWARE: FastSEQ for Windows Version 2.0

35

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: TO BE ASSIGNED

(B) FILING DATE: 30-MAY-1997

40

(C) CLASSIFICATION: UNKNOWN

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:

45

(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

50

(A) NAME: CRUMP, Julian Richard John

(B) REGISTRATION NUMBER: 37127

(C) REFERENCE/DOCKET NUMBER: GH-70055

55

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: +44 171 405 5875

(B) TELEFAX: +44 171 831 0749

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4203 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCTTCCATCC	TAATACAACT	CACTATAGGG	CTCGAGCGGC	CGCCCGGGCA	GGTGCTTGAC	60
GGAGGTGCCT	GTGCACCCCC	TCAGCAATCT	GCCCACCCTA	CAGGCGCTGA	CCCTGGCTCT	120
CAACAAGATC	TCAAGCATCC	CTGACTTTGC	ATTTACCAAC	CTTTCAAGCC	TGGTAGTTCT	180
GCATCTTCAT	AACAATAAAA	TTAGAAGCCT	GAGTCAACAC	TGTTTTGATG	GACTAGATAA	240
CCTGGAGACC	TTAGACTTGA	ATTATAATAA	CTTGGGGGAA	TTTCCTCAGG	CTATTAAAGC	300
CCTTCCTAGC	CTTAAAGAGC	TAGGATTTCA	TAGTAATTCT	ATTTCTGTTA	TCCCTATGGA	360
GCATTTGATG	GTAATCCACT	CTTAAGAACT	ATACATTTGT	ATGATAATCC	TCTGTCTTTT	420
GTGGGGA ACT	CAGCATTTCA	CAATTTATCT	GATCTTCATT	CCCTAGTCAT	TCGTGGTGCA	480
AGCATGGTGC	AGCAGTTCCC	CAATCTTACA	GGAAGTGTCC	ACCTGGAAAG	TCTGACTTTG	540
ACAGGTACAA	AGATAAGCAG	CATACCTAAT	AATTTGTGTC	AAGAACAAAA	GATGCTTAGG	600
ACTTTGGACT	TGTCTTACAA	TAATATAAGA	GACCTTCCAA	GTTTTAATGG	TTGCCATGCT	660
CTGGAAGAAA	TTTCTTTACA	GCGTAATCAA	ATCTACCAAA	TAAAGGAAGG	CACCTTTCAA	720
GGCCTGATAT	CTCTAAGGAT	TCTAGATCTG	AGTAGAAACC	TGATACATGA	AATTCACAGT	780
AGAGCTTTTG	CCACACTTGG	GCCAATAACT	AACCTAGATG	TAAGTTTCAA	TGAATTAACT	840
TCCTTTCCTA	CGGAAGGCCT	GAATGGGCTA	AATCAACTGA	AACTGGTGGG	CAACTTCAAG	900
CTGAAAGAAG	CCTTAGCAGC	AAAAGACTTT	GTTAACCTCA	GGTCTTTATC	AGTACCATAT	960
GCTTATCAGT	GCTGTGCATT	TTGGGGTTGT	GACTCTTATG	CAAATTTAAA	CACAGAAGAT	1020
AACAGCCTCC	AGGACCACAG	TGTGGCACAG	GAGAAAGGTA	CTGCTGATGC	AGCAAATGTC	1080
ACAAGCACTC	TTGAAAATGA	AGAACATAGT	CAAATAATTA	TCCATTGTAC	ACCTTCAACA	1140
GGTGCTTTTA	AGCCCTGTGA	ATATTTACTG	GGAAGCTGGA	TGATTCGTCT	TACTGTGTGG	1200
TTCATTTTCT	TGGTTGCATT	ATTTTTCAAC	CTGCTTGTTA	TTTAAACAAC	ATTTGCATCT	1260
TGTACATCAC	TGCCTTCGTC	CAAATTGTTT	ATAGGCTTGA	TTTCTGTGTC	TAAC TTATTC	1320
ATGGGAATCT	ATACTGGCAT	CCTAACTTTT	CTTGATGCTG	TGTCCTGGGG	CAGATTCGCT	1380
GAATTTGGCA	TTTGGTGGGA	AACTGGCAGT	GGCTGCAAAG	TAAC TGGGTT	TCTTGCAGTT	1440

EP 0 881 289 A2

	TTCTCCTCAG	AAAGTGCCAT	ATTTTATTATTA	ATGCTAGCAA	CTGTCGAAAG	AAGCTTATCT	1500
	GCAAAAGATA	TAATGAAAAA	TGGGAAGAGC	AATCATCTCA	AACAGTTCCG	GGTTGCTGCC	1560
5	CTTTTGGCTT	TCCTAGGTGC	TACAGTAACA	GGCTGTTTTT	CCCTTTTCCA	TAGAGGGGAA	1620
	TATTCTGCAT	CACCCCTTTG	TTTGCCATTT	CCTACAGGTG	AAACGCCATC	ATTAGGATTC	1680
	ACTGTAACGT	TAGTGCTATT	AAACTCACTA	GCATTTTTTAT	TAATGGCCGT	TATCTACACT	1740
	AAGCTATACT	GCAACTTGGA	AAAAGAGGAC	CTCTCAGAAA	ACTCACAATC	TAGCATGATT	1800
10	AAGCATGTCG	CTTGGCTAAT	CTTCACCAAT	TGCATCTTTT	TCTGCCCTGT	GGCGTTTTTT	1860
	TCATTTGCAC	CATTGATCAC	TGCAATCTCT	ATCAGCCCCG	AAATAATGAA	GTCTGTTACT	1920
	CTGATATTTT	TTCCATTGCC	TGCTTGCCCTG	AATCCAGTCC	TGTATGTTTT	CTTCAACCCA	1980
	AAGTTTAAAG	AAGACTGGAA	GTTACTGAAG	CGACGTGTTA	CCAAGAAAAG	TGGATCAGTT	2040
15	TCAGTTTCCA	TCAGTAGCCA	AGGTGGTTGT	CTGGAACAGG	ATTTCTACTA	CGACTGTGGC	2100
	ATGTACTCAC	ATTTGCAGGG	CAACCTGACT	GTTTGCGACT	GCTGCGAATC	GTTTCTTTTA	2160
	ACAAAGCCAG	TATCATGCAA	ACACTTGATA	AAATCACACA	GCTGTCCTGC	ATTGGCAGTG	2220
	GCTTCTTGCC	AAAGACCTGA	GGGCTACTGG	TCCGACTGTG	GCACACAGTC	GGCCCACTCT	2280
20	GATTATGCAG	ATGAAGAAGA	TTCCTTTGTC	TCAGACAGTT	CTGACCAGGT	GCAGGCCTGT	2340
	GGACGAGCCT	GCTTCTACCA	GAGTAGAGGA	TTCCCTTTGG	TGCGCTATGC	TTACAATCTA	2400
	CCAAGAGTTA	AAGACTGAAC	TACTGTGTGT	GTAACCGTTT	CCCCCGTCAA	CCAAATCAG	2460
	TGTTTATAGA	GTGAACCCTA	TTCTCATCTT	TCATCTGGGA	AGCACTTCTG	TAATCACTGC	2520
25	CTGGTGTGAC	TTAGAAGAAG	GAGAGGTGGC	AGTTTATTTC	TCAAACCAGT	CATTTTCAAA	2580
	GAACAGGTGC	CTAAATTATA	AATTGGTGAA	AAATGCAATG	TCCAAGCAAT	GTATGATCTG	2640
	TTTGAAACAA	ATATATGACT	TGAAAAGGAT	CTTAGGTGTA	GTAGAGCAAT	ATAATGTTAG	2700
	TTTTTTCTGA	TCCATAAGAA	GCAAAATTTAT	ACCTATTTGT	GTATTAAGCA	CAAGATAAAG	2760
30	AACAGCTGTT	AATATTTTTT	AAAAATCTAT	TTTAAAATGT	GATTTTCTAT	AACTGAAGAA	2820
	AATATCTTGC	TAATTTTACC	TAATGTTTCA	TCCTTAATCT	CAGGACAACT	TACTGCAGGG	2880
	CCAAAAAAGG	GACTGTCCCA	GCTAGAACTG	TGAGAGTATA	CATAGGCATT	ACTTTATTAT	2940
	GTTTTCACTT	GCCATCCTTG	ACATAAGAGA	ACTATAAATT	TTGTTTAAGC	AATTTATAAA	3000
35	TCTAAAACCT	GAAGATGTTT	TTAAAACAAT	ATTAACAGCT	GTTAGGTTAA	AAAAATAGCT	3060
	GGACATTTGT	TTTCAGTCAT	TATACATTGC	TTTGGTCCAA	TCAGTAATTT	TTTCTTAAGT	3120
	GTTTTGTGAT	TACACTACTA	GAAAAAAAGT	AAAAGGCTAA	TTGCTGTGTG	GGTTTAGTCG	3180
	ATTTGGCTAA	ACTACTAACT	AATGTGGGGG	TTTAATAGTA	TCTGAGGGAT	TTGGTGGCTT	3240
40	CATGTAATGT	TCTCATTAAT	GAATACTTCC	TAATATCGTT	GGCTCTACTA	ATATTTTCCA	3300
	ATTTGCTGGG	ATGTCACCTA	GCAATAGCTT	GGATTATATA	GAAAGTAAAC	TGTGGTCAAT	3360
	ACTTGCAATTT	AATTAGACGA	AACGGGGAGT	AATTATGACA	CGAAGTACTT	ATGTTTATTT	3420
	CTTAGTGAGC	TGGATTATCT	TGAACCTGTG	CTATTAAATG	GAAATTTCCA	TACATCTTCC	3480
45	CCATACTATT	TTTTATAAAA	GAGCCTATTG	AATAGCTCAG	AGGTTGAACT	CTGGTTAAAC	3540
	AAGATAATAT	GTTATTAATA	AAAATAGAAG	AAGAAAGAAT	AAAGCTTAGT	CCTGTGTCTT	3600
	TAAAAATTAA	AAATTTTACT	TGATTCCCAT	CTATGGGCTT	TAGACCTATT	ACTGGGTGGA	3660
	GTCTTAAAGT	TATAATTGTT	CAATATGTTT	TTTGAACAGT	GTGCTAAATC	AATAGCAAAC	3720
50	CCACTGCCAT	ATTAGTTATT	CTGAATATAC	TAAAAAATC	CAGCTAGATT	GCAGTTTAAT	3780
	AATTAAACTG	TACATACTGT	GCATATAATG	AATTTTATATC	TTATGTAAAT	TATTTTATAGA	3840
	ACACAAGTTG	GGAAATGTGG	CTTCTGTTCA	TTTCGTTTAA	TTAAAGCTAC	CTCCTAAACT	3900
55	ATAGTGCGCTG	CCAGTAGCAG	ACTGTTAAAT	TGTGGTTTAT	ATACTTTTTG	CATTGTAAAT	3960

AGTCTTTGTT GTACATTGTC AGTGTAATAA AACAGAATC TTTGTATATC AAAATCATGT 4020
 AGTTTGTATA AAATGTGGGA AGGATTTATT TACAGTGTGT TGTAATTTTG TAAGGCCAAC 4080
 5 TATTTACAAG TTTTAAAAAT TGCTATCATG TATATTTACA CATCTGATAA ATATTAAATC 4140
 ATAACCTGGT AAGAACTCC TAATTAAAAG GTTTTTTCCA AAAAAAAAAA AAAAAAAAAA 4200
 AAA 4203

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 644 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Val Gln Gln Phe Pro Asn Leu Thr Gly Thr Val His Leu Glu Ser
 1 5 10 15
 25 Leu Thr Leu Thr Gly Thr Lys Ile Ser Ser Ile Pro Asn Asn Leu Cys
 20 25 30
 Gln Glu Gln Lys Met Leu Arg Thr Leu Asp Leu Ser Tyr Asn Asn Ile
 35 40 45
 30 Arg Asp Leu Pro Ser Phe Asn Gly Cys His Ala Leu Glu Glu Ile Ser
 50 55 60
 Leu Gln Arg Asn Gln Ile Tyr Gln Ile Lys Glu Gly Thr Phe Gln Gly
 65 70 75 80
 35 Leu Ile Ser Leu Arg Ile Leu Asp Leu Ser Arg Asn Leu Ile His Glu
 85 90 95
 Ile His Ser Arg Ala Phe Ala Thr Leu Gly Pro Ile Thr Asn Leu Asp
 100 105 110
 40 Val Ser Phe Asn Glu Leu Thr Ser Phe Pro Thr Glu Gly Leu Asn Gly
 115 120 125
 Leu Asn Gln Leu Lys Leu Val Gly Asn Phe Lys Leu Lys Glu Ala Leu
 130 135 140
 45 Ala Ala Lys Asp Phe Val Asn Leu Arg Ser Leu Ser Val Pro Tyr Ala
 145 150 155 160
 Tyr Gln Cys Cys Ala Phe Trp Gly Cys Asp Ser Tyr Ala Asn Leu Asn
 165 170 175
 50 Thr Glu Asp Asn Ser Leu Gln Asp His Ser Val Ala Gln Glu Lys Gly
 180 185 190
 Thr Ala Asp Ala Ala Asn Val Thr Ser Thr Leu Glu Asn Glu Glu His

EP 0 881 289 A2

	195		200		205	
	Ser Gln Ile Ile Ile His Cys Thr Pro Ser Thr Gly Ala Phe Lys Pro					
5	210		215		220	
	Cys Glu Tyr Leu Leu Gly Ser Trp Met Ile Arg Leu Thr Val Trp Phe					
	225		230		235	240
	Ile Phe Leu Val Ala Leu Phe Phe Asn Leu Leu Val Ile Leu Thr Thr					
10		245		250		255
	Phe Ala Ser Cys Thr Ser Leu Pro Ser Ser Lys Leu Phe Ile Gly Leu					
		260		265		270
	Ile Ser Val Ser Asn Leu Phe Met Gly Ile Tyr Thr Gly Ile Leu Thr					
15		275		280		285
	Phe Leu Asp Ala Val Ser Trp Gly Arg Phe Ala Glu Phe Gly Ile Trp					
	290		295		300	
	Trp Glu Thr Gly Ser Gly Cys Lys Val Thr Gly Phe Leu Ala Val Phe					
20	305		310		315	320
	Ser Ser Glu Ser Ala Ile Phe Leu Leu Met Leu Ala Thr Val Glu Arg					
		325		330		335
	Ser Leu Ser Ala Lys Asp Ile Met Lys Asn Gly Lys Ser Asn His Leu					
		340		345		350
25	Lys Gln Phe Arg Val Ala Ala Leu Leu Ala Phe Leu Gly Ala Thr Val					
		355		360		365
	Thr Gly Cys Phe Pro Leu Phe His Arg Gly Glu Tyr Ser Ala Ser Pro					
30	370		375		380	
	Leu Cys Leu Pro Phe Pro Thr Gly Glu Thr Pro Ser Leu Gly Phe Thr					
	385		390		395	400
	Val Thr Leu Val Leu Leu Asn Ser Leu Ala Phe Leu Leu Met Ala Val					
		405		410		415
35	Ile Tyr Thr Lys Leu Tyr Cys Asn Leu Glu Lys Glu Asp Leu Ser Glu					
		420		425		430
	Asn Ser Gln Ser Ser Met Ile Lys His Val Ala Trp Leu Ile Phe Thr					
		435		440		445
40	Asn Cys Ile Phe Phe Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu					
		450		455		460
	Ile Thr Ala Ile Ser Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu					
	465		470		475	480
45	Ile Phe Phe Pro Leu Pro Ala Cys Leu Asn Pro Val Leu Tyr Val Phe					
		485		490		495
	Phe Asn Pro Lys Phe Lys Glu Asp Trp Lys Leu Leu Lys Arg Arg Val					
		500		505		510
50	Thr Lys Lys Ser Gly Ser Val Ser Val Ser Ile Ser Ser Gln Gly Gly					
		515		520		525
	Cys Leu Glu Gln Asp Phe Tyr Tyr Asp Cys Gly Met Tyr Ser His Leu					

55

EP 0 881 289 A2

530 535 540
 Gln Gly Asn Leu Thr Val Cys Asp Cys Cys Glu Ser Phe Leu Leu Thr
 545 550 555 560
 Lys Pro Val Ser Cys Lys His Leu Ile Lys Ser His Ser Cys Pro Ala
 565 570 575
 Leu Ala Val Ala Ser Cys Gln Arg Pro Glu Gly Tyr Trp Ser Asp Cys
 580 585 590
 Gly Thr Gln Ser Ala His Ser Asp Tyr Ala Asp Glu Glu Asp Ser Phe
 595 600 605
 Val Ser Asp Ser Ser Asp Gln Val Gln Ala Cys Gly Arg Ala Cys Phe
 610 615 620
 Tyr Gln Ser Arg Gly Phe Pro Leu Val Arg Tyr Ala Tyr Asn Leu Pro
 625 630 635 640
 Arg Val Lys Asp

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 473 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGCACGAGAA CGCCATCATT AGGATTCCT GTAACTTAG TGCTATTAAA CTCCTAGCA 60
 TTTTATTAA TGCCGTTAT CTACACTAAG CTATACTGCA ACTTGGAATA AGAGGACCTC 120
 TCAGAAACT CACAATCTAG CATGATTAAG CATGTCGCTT GGCTAATCTT CACCAATTGC 180
 ATCTTTTCT GCCCTGTGGC GTTTTTTCA TTTGCACCAT TGATCACTGC AATCTCTATC 240
 AGCCCCGAAA TAATGAAGTC TGTTACTCTG ATATTTTTTC CATTGCCTGC TTGCCTGAAT 300
 CCAGTCCTGT ATGTTTCTT CAACCCAAAG TTAAAGAGG ACTGGGAAGT TACTGAGGCG 360
 ACGTGTTTAC CAGGAAAAGT GGGTCCAGT TCAGTTNCCN CATAGNCCAG GTGGTTTCTG 420
 GAACAGGGT TNTATAGGT TTGGGATGTA CTCACATNG AAGGCAACCT GAC 473

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AGTTAGGATG CCAGTATAGA TTCCC

25

Claims

1. An isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the Novel 7TM receptor (H2CAA71) polypeptide of SEQ ID NO:2 over its entire length; or a nucleotide sequence complementary to said isolated polynucleotide.
2. The polynucleotide of claim 1 which is DNA or RNA.
3. The polynucleotide of claim 1 wherein said polynucleotide comprises a nucleotide sequence that has at least 80% identical to that of SEQ ID NO:1 over its entire length.
4. The polynucleotide of claim 3 wherein said nucleotide sequence comprises the Novel 7TM receptor (H2CAA71) polypeptide encoding sequence contained in SEQ ID NO:1.
5. The polynucleotide of claim 3 which is polynucleotide of SEQ ID NO: 1.
6. A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing a Novel 7TM receptor (H2CAA71) polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO:2 when said expression system is present in a compatible host cell.
7. A host cell comprising the expression system of claim 6.
8. A process for producing a Novel 7TM receptor (H2CAA71) polypeptide comprising culturing a host of claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.
9. A process for producing a cell which produces a Novel 7TM receptor (H2CAA71) polypeptide thereof comprising transforming or transfecting a host cell with the expression system of claim 6 such that the host cell, under appropriate culture conditions, produces a Novel 7TM receptor (H2CAA71) polypeptide.
10. A Novel 7TM receptor (H2CAA71) polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO:2 over its entire length.
11. The polypeptide of claim 10 which comprises the amino acid sequence of SEQ ID NO:2.
12. An antibody immunospecific for the Novel 7TM receptor (H2CAA71) polypeptide of claim 10.
13. A method for the treatment of a subject in need of enhanced activity or expression of Novel 7TM receptor (H2CAA71) polypeptide of claim 10 comprising:
 - (a) administering to the subject a therapeutically effective amount of an agonist to said receptor; and/or
 - (b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the Novel 7TM receptor (H2CAA71) polypeptide of SEQ ID NO:2 over its entire length; or a nucleotide sequence complementary to said nucleotide sequence in a form so as to effect production of said polypeptide activity *in vivo*.
14. A method for the treatment of a subject having need to inhibit activity or expression of Novel 7TM receptor

(H2CAA71) polypeptide of claim 10 comprising:

- (a) administering to the subject a therapeutically effective amount of an antagonist to said receptor; and/or
- (b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said receptor; and/or
- (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said receptor for its ligand.

15. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of Novel 7TM receptor (H2CAA71) polypeptide of claim 10 in a subject comprising:

- (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said Novel 7TM receptor (H2CAA71) polypeptide in the genome of said subject; and/or
- (b) analyzing for the presence or amount of the Novel 7TM receptor (H2CAA71) polypeptide expression in a sample derived from said subject.

16. A method for identifying agonists to Novel 7TM receptor (H2CAA71) polypeptide of claim 10 comprising:

- (a) contacting a cell which produces a Novel 7TM receptor (H2CAA71) polypeptide with a candidate compound; and
- (b) determining whether the candidate compound effects a signal generated by activation of the Novel 7TM receptor (H2CAA71) polypeptide.


17. An agonist identified by the method of claim 16.

18. A method for identifying antagonists to Novel 7TM receptor (H2CAA71) polypeptide of claim 10 comprising:

- (a) contacting a cell which produces a Novel 7TM receptor (H2CAA71) polypeptide with an agonist; and
- (b) determining whether the signal generated by said agonist is diminished in the presence of a candidate compound.

19. An antagonist identified by the method of claim 18.

This Page Blank (uspto)



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 881 289 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
26.01.2000 Bulletin 2000/04

(43) Date of publication A2:
02.12.1998 Bulletin 1998/49

(21) Application number: 97309254.7

(22) Date of filing: 18.11.1997

(51) Int. Cl.⁷: **C12N 15/12**, C12N 5/10,
C07K 14/705, C07K 16/28,
A61K 31/70, A61K 38/17,
A61K 48/00, C12Q 1/68,
G01N 33/50, G01N 33/68

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(30) Priority: 30.05.1997 US 866757

(71) Applicant:
**SMITHKLINE BEECHAM CORPORATION
Philadelphia Pennsylvania 19103 (US)**

(72) Inventors:
• **Elshourbagy, Nabil A.
King of Prussia, Pennsylvania 19406 (US)**

• **Li, Xiaotong
King of Prussia, Pennsylvania 19406 (US)**
• **Bergsma, Derk, J.
King of Prussia, Pennsylvania 19406 (US)**

(74) Representative:
**Crump, Julian Richard John et al
FJ Cleveland,
40-43 Chancery Lane
London WC2A 1JQ (GB)**

(54) **Novel 7TM receptor (H2CAA71)**

(57) Novel 7TM receptor (H2CAA71) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Novel 7TM receptor (H2CAA71) polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, among others and diagnostic assays for such conditions.

EP 0 881 289 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 97 30 9254 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	DATABASE EMBEST27 [Online] E.M.B.L. Databases Accession Number: AA313513, 18 April 1997 (1997-04-18) ADAMS M ET AL: "Homo sapiens cDNA 5' end similar to similar lutropin-choriogonadotropic hormone receptor" XP002123850 99.2% identity in 361nt overlap with SeqIdNo.1 * abstract *	1-11	C12N15/12 C12N5/10 C07K14/705 C07K16/28 A61K31/70 A61K38/17 A61K48/00 C12Q1/68 G01N33/50 G01N33/68
E	--- WO 99 15545 A (MCDONALD TERRENCE P ;LIU QINGYUN (US); ABRAMOVITZ MARK (US); MERCK) 1 April 1999 (1999-04-01) * claims 1-12 *	1-16,18	
E	--- WO 98 45436 A (GENETICS INST) 15 October 1998 (1998-10-15) SeqIdNo.1232: 97.6% identity in 125aa overlap with SeqIdNo.2 / 99.7% identity in 370nt overlap with SeqIdNo.1 --- -/--	1-3	TECHNICAL FIELDS SEARCHED (Int.Cl.6) C12N C07K A61K C12Q G01N
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		25 November 1999	Lonnoy, 0
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 82 (P4/C07)

PARTIAL EUROPEAN SEARCH REPORT

EPO FORM 1500 03.12 (P04C10)

3

European Patent
OfficeINCOMPLETE SEARCH
SHEET CApplication Number
EP 97 30 9254

Although claims 13 and 14 are directed to methods of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compounds/compositions.

Claim(s) not searched:
17,19

Reason for the limitation of the search:

Claims 13, 14, 17 and 19 refer to an antagonist to the polypeptide of claim 10, an agonist to the polypeptide of claim 10, to the use of said antagonist and to the use of said agonist, without giving a true technical characterization. Moreover, no such compound is defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such speculative claims as claim 17 and claim 19, nor for the corresponding subject-matters of claims 13 and 14, claims the wording of which is, in fact, a mere recitation of the results to be achieved.

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 97 30 9254

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

25-11-1999

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9915545	A	01-04-1999	NONE		
WO 9845436	A	15-10-1998	AU	6891098 A	30-10-1998
WO 9013643	A	15-11-1990	AT	115409 T	15-12-1994
			AU	5732190 A	29-11-1990
			DE	69015175 D	26-01-1995
			DE	69015175 T	29-06-1995
			DK	471030 T	29-05-1995
			EP	0471030 A	19-02-1992
			EP	0614975 A	14-09-1994
			ES	2068388 T	16-04-1995
			JP	4505103 T	10-09-1992
WO 9711194	A	27-03-1997	US	5851768 A	22-12-1998
			AU	6990296 A	09-04-1997

EPO FORM PM/59

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

This Page Blank (uspto)